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Have biomarkers been identiﬁed by proteomics? Have diseases treatments been changed
based on proteomic ﬁndings? The straight answer is “no”, considering the huge amount
of  data generated by proteomic studies and the number of available biomarkers and
proteomic-based clinical solutions implemented so far. Thus far, the science of proteomics
has dedicated most of its attention to technological aspects, which has reached an apex.
Now  it is time to apply such technology to pertinent biological questions in order to gen-
ench to bedside erate  groundbreaking results biologically relevant. Furthermore, the concept of biomarker
must  be properly applied in proteomic studies, considering speciﬁcity, sensitivity and sta-
tistical power. These are some of the several steps that proteomic studies must follow to
approximate the bench to bedside in the next years.
After the release of the Human Genome Project (HGP) data,
he A decrease in efﬁciency in the development of new drugs for
uman diseases has been observed in clinical trials, resulting
n losses of millions of dollars for pharmaceuticals indus-
ries. Such impact boosted the creation of alternative methods
nd new tools aiming to increase the success rate of clinical
tudies. Clinical proteomics, an interdisciplinary ﬁeld which
pplies proteomic methods to address clinical questions, has
merged as a potential ﬁeld for improving the discovery
nd development of new and efﬁcient drugs on lesser costs.
© 2013 Tmong the alternatives provided by this ﬁeld, the search for
olecular biomarkers which could be translated into clinical
ools deserves attention. These biomarkers offer a promise
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Additionally, they could be used to monitor treatments, direc-
ting patients to the use of the most efﬁcient drugs, and, last but
not least, point targets for the development of new drugs [1,2].
1.  “Omics”  studies  for  biomarkers
discovery  and  development
 
uthors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.ics and Biomarkers, Kraepelinstr. 2-10, 80804 Munich, Germany.
many  hopes were nurtured in the development of disease
genomic biomarkers. “Omics” approaches allowed the quest
 CC BY-NC-ND license.
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for speciﬁc molecular signatures in diseases and better com-
prehension of pathological processes. Besides that, a general
thought that it would be possible to replace promiscuous
biomarkers for more  speciﬁc molecules, especially proteins,
has boosted high throughput proteomic techniques into ambi-
tious ﬂights in a short time. However, over a decade later and
after hundreds of genomic markers candidates related to dis-
eases and its phenotypes, one may still see a lack of clinically
useful biomarkers. Only few were translated for clinical means
and many  of these were already known even before the HGP
[3–6].
2.  From  transcriptomics  to  proteomics
Considering the advanced stage of mRNA  large-scale
screening technologies and mRNA’s dynamic nature, trans-
criptome analysis became a popular tool to unravel character-
istics of gene expression at the beginning of the post-genomic
era. A large number of expression proﬁles from several dif-
ferent diseases and/or treatments were published, employing
techniques like microarrays or serial analysis of gene expres-
sion (SAGE). However, the poor correlation between mRNA  and
proteins levels, due to alternative splicing and lack of mRNA
in some body ﬂuids for example, led scientists to assume that
evaluating the protein expression as a measurement of gene
activity would be also necessary [3,6–12].
3.  Proteomics  in  biomarker  discovery:  why
and  how?
The dynamic nature of the proteome, combined with the fact
that proteins are the active cellular agents, allows the com-
parison of different expression proﬁles in different conditions
(e.g. control vs. disease or treated vs. non-treated), in order
to reveal proteins as potential biomarker candidates [12–14].
Another advantage of proteomic analyses is the characteriza-
tion of proteins post translational modiﬁcations (PTM) such
as phosphorylation, glycosylation, acetylation and oxidation,
which are often linked to disease pathophysiology and are use-
ful targets on therapeutics. Analyses can basically be divided
into two-dimensional gel electrophoresis 2DE and shotgun
mass spectrometry. While 2DE relies on direct measurements
of spots intensities, shotgun mass spectrometry can be quan-
tiﬁed by label-based or label-free methods. Each of these
methods has strengths and weaknesses, making them rather
complementary than better to each other, when the focus is
achieving the best proteome coverage possible [4,8,12–15].
4.  Metabolomics:  towards  an  integromics
Techniques like mass spectrometry (MS) and nuclear magnetic
resonance (NMR) evolved to the large-scale analyses of small
molecules paving the way to metabolomic analyses, which can
also reveal molecular biomarkers. Analysis of metabolites on
a biological system is justiﬁed by the variation on the global
levels of these in a given disease, treatment or toxicity situa-
tion. The variation in metabolite levels corresponds to a reﬂex
of what occurs to be upstream to gene and protein expression i c s 1 ( 2 0 1 3 ) 53–56
[16]. Monitoring the levels of these small molecules in body ﬂu-
ids such as saliva, urine or blood serum or plasma, which can
be collected in a non-invasive manner, would provide a large
advance in modern medicine, but technical and instrumental
challenges for this discipline still hamper clinical translation
of existing data [16,17].
The intricate relation among nucleic acids, proteins and
metabolites are the bases of systems biology studies, which
aim for understanding pathologies more  exhaustively and
identifying biomarker candidates. However, scientists still
struggle to integrate data from these different areas, consid-
ering the differences in technologies. For example, protein
science does not provide of any similar technique to PCR,
the basis of DNA studies. Microarray data are still more
sensitive than proteomic analyses on generating differences
in the detection of molecules that have the potential to
be employed as biomarkers. Therefore, scientists currently
are pushing technological boundaries in order to be able
integrating data. Integration of these ‘omic datasets or inte-
gromics is desirable as it links the individual biological
elements to provide a more  complete understanding of
dynamic biological processes [18,19]. Attempts to confront
and merge  proteomic and metabolomic data have been con-
ducted for some pathologies, but still many  issues need to be
circumvented [20–22].
5.  Challenges  to  overcome  in  biomarker
research
Proteomics is one of the major hopes to discover biomarker
candidates with potential to be translated to clinical practice.
After more  than one decade of comparative proteomics of dis-
eases, a massive amount of information has been generated,
but the desired biomarkers have not been acquired in the same
extent [23,24].
Among the main requirements to achieve clinically use-
ful biomarkers, proteomic studies need sensitivity, accuracy,
reproducibility and high sample throughput. Technology-
wise, state-of-the-art shotgun mass spectrometry has reached
a state which fulﬁlls all these requirements. Hence, now it
is time to move the attention to the biological point of view
in order to identify useful biomarkers employing the very
powerful techniques developed in the past years. Biology-
wise, sensitivity is still a pivotal issue, depending on the
sample to be investigated and used platform. For example,
the dynamic range is an issue regarding the identiﬁcation of
low-abundant proteins. Depletion of high abundant proteins
must be performed for proteomic studies in blood serum or
plasma, considering that protein concentrations spanning 12
orders of magnitude in this tissue [25]. But this method entails
some limitations such as the removal of proteins which are
bound to those targeted to be depleted [26]. Reproducibility
can be affected by several sources of noise, such as sample
collection and handling (including all pre-analytical steps),
individual variability from patients/control (considering dif-
ferent genetic background and life styles) – and cohort size,
which in most studies is signiﬁcantly smaller than the inci-
dence of the studied disease. Regarding the number of samples
analyzed, proteomics still present this limitation since it is
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nconceivable to date to analyze, for example, the proteome
f 1000 samples in a single experiment or at least in a sin-
le round of experiment employing any kind of quantitative
echnology available thus far – label-based or label-free. For
xample, 1000 samples represent 0.003% of the number of peo-
le affected by schizophrenia, suggesting the low power of
iscovering biomarkers using proteomics, especially consid-
ring schizophrenia’s polygenetic background. A proteomic
echnique that has shown potential to help in this regard is the
elected/multiple reaction monitoring (SRM or MRM), which
llows the accurate quantiﬁcation in a targeted manner of pro-
ein candidates through the analysis of proteotypic peptides.
RM analyses will be based in a panel of biomarker candi-
ates pre-deﬁned in a “discovery study” for a given disease.
owever, discovery studies are mostly underpowered by the
educed number of samples analyzed.
The technological high throughput by proteomics offers
he possibility to overcome the limitation of searching for
iomarkers at only one tissue and/or body ﬂuid, allowing
his way a higher success rate of putative biomarkers, since
he presence of such a molecule in different body locations
ncreases its feasibility [27,28].
One conceptual serious issue on biomarker research is
romoted by disease heterogeneity. For achieving clinically
pplicable biomarkers, patient stratiﬁcation and phenotype
haracterization for revealing the heterogeneity of the disease
f interest as well as a priori data modeling must be incor-
orated to the pipeline of the study. These data would point
t least if the disease of interest is suitable for an “omics”
pproach or not, avoiding lack of robustness of biomarker can-
idates [29].
Bioinformatics is also a ﬁeld for improvements aiming at
trategic help to deal with the generated data towards the
evelopment of clinical biomarkers. With the evolution of MS-
ased proteomics and the large amount of data provided over
he last decade, “hypothesis-driven” approaches require efﬁ-
ient tools to reduce the information available, classify and
llow visualization and text mining, all in a comprehensive
anner [23,30].
Statistical analysis is an essential tool for biomedical
esearch, which is also true for large-scale “omics” studies –
ypothesis-driven or not. This tool must be tuned to allow
etecting and validating subtle differences in concentrations
f cellular entities (i.e. proteins, nucleic acids or metabolites)
31]. The application of proteomic studies on clinical investi-
ation has completed almost two decades of full activity, but
nly recently attention has been paid to the integration and
alidation of proteomic data with proper statistical tools. In
cientiﬁc literature, it is common to ﬁnd a lack of appropriate
xperimental design as well as random criteria for data analy-
is without any pre-validation experiments. For example, the
IGE technique following the proposed experimental design
f Alban and colleagues [32] was adopted on several stud-
es that have been published with no pilot experiment that
ould reveal biological and technical variations, which could
ndicate the correct choice for number of technical and/or
iological replicates, size effect and fold changes to be used.
his way, results lack statistical reliability, directly affecting
heir conclusions and validity. Karp and colleagues addressed
ome issues related to this speciﬁc proteomic platform, giving c s 1 ( 2 0 1 3 ) 53–56 55
orientations for the deﬁnition of several statistical criteria to
improve results [33–35].
The articles of Lewis and colleagues are good examples of
how to employ statistics rigorously on proteomic analysis of
dystrophic muscles, managing to combine high sensitivity and
statistical power[36,37].
At another study, Karp and colleagues address in an intel-
ligent manner the problem of the multiple hypothesis error,
not properly considered before in proteomics, using statistical
platforms previously applied to genome-wide studies [33,38].
Appropriated experimental design and methodological
pre-validation, including statistics, will improve the quality
of the study and reduce its costs. In turn, these will enhance
the comprehension of the biological mechanisms of interest,
and will provide robust biomarker candidates [39].
6.  Concluding  remarks  and  future
perspectives
By employing proteomics as a non-hypothesis driven
approach, a comprehensive view about the molecular patho-
logical conditions on a disease without considering previous
ﬁndings may be generated and new directions for further stud-
ies may be provided. Thus, proteomics has the potential to
be a suitable tool on drug development, treatment evaluation
and categorization of patients. However, for translating basic
research into useful clinical tools, proteomic studies should
turn the focus into relevant biological questions rather than
proteomic technology. From now on, clinical studies must
make use of the range of very powerful instrumentation, tech-
niques and approaches which have been developed thus far in
favor of the biology. This way, proteomics will be a useful tool
for aiding human diseases effectively by approximating bench
to bedside.
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